ERBB2 Exon 20 Insertion

CI-VAR-00001011Explore in graph →CIViC 2854

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma6
ERBB2 Exon 20 Insertion	Poziotinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID12132 Ninety patients (pre-treated with a median of 2 lines of therapy) with Non-Small Cell Lung Cancer harbouring HER2 exon 20 insertion mutations were treated with poziotinib. The ORR was 27.8% (95% CI, 1… (full text at CIViC) PMID 34843401 · Le et al., 2022 · Open in CIViC	civic
ERBB2 Exon 20 Insertion	Poziotinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID12133 Eighty pre-treated patients with Non-Small Cell Lung Cancer harbouring HER2 exon 20 insertions were treated with poziotinib. The ORR Was 39% (95% CI, 28%-50%), and 80% of the patients had a tumour red… (full text at CIViC) PMID 36958688 · Cornelissen et al., 2023 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.